Are Cardiometabolic and Endocrine Abnormalities Linked to Sleep Difficulties in Schizophrenia? A Hypothesis Driven Review

키워드

참고문헌 (159)

1. Jablensky A, "Schizophrenia: recent epidemiologic issues", Epidemiol Rev, 17, pp.10~20 (1995)
2. Tandon R, "Schizophrenia,“just the facts” what we know in 2008. 2. Epidemiologyand etiology", Schizophr Res, 102, pp.1~18 (2008)
3. Bora E, "Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study", Br J Psychiatry, 195, pp.475~482 (2009)
4. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders IV revised" (2000), American Psychiatric Publishing
5. Monti JM, "Sleep disturbance in schizophrenia", Int Rev Psychiatry, 17, pp.247~253 (2005)
6. Spiegel K, "Impact of sleep debt on metabolic and endocrine function", Lancet, 354, pp.1435~1439 (1999)
7. Haffmans PM, "Sleep disturbance in schizophrenia", Br J Psychiatry, 165, pp.697~698 (1994)
8. Royuela A, "Sleep in schizophrenia: a preliminary study using the Pittsburgh Sleep Quality Index", Neurobiol Sleep-Wakefulness Cycle, 2, pp.37~39 (2002)
9. Smith M, "First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis", Br J Psychiatry, 192, pp.406~411 (2008)
10. BorbéEly AA., "A two process model of sleep regulation", Hum Neurobiol, 1, pp.195~204 (1982)
11. Achermann P, "A model of human sleep homeostasis based on EEG slow-wave activity: quantitative comparison of data and simulations", Brain Res Bull, 31, pp.97~113 (1993)
12. Akerstedt T, "The three-process model of alertness and its extension to performance, sleep latency, and sleep length", Chronobiol Int, 14, pp.115~123 (1997)
13. Chouinard S, "Sleep in untreated patients with schizophrenia: a meta-analysis", Schizophr Bull, 30, pp.957~967 (2004)
14. Zarcone VP Jr, "Abnormal rapid eye movement latencies in schizophrenia", Arch Gen Psychiatry, 44, pp.45~48 (1987)
15. Feinberg I, "Stage 4 sleep in schizophrenia", Arch Gen Psychiatry, 21, pp.262~266 (1969)
16. Benson KL, "Sleep in schizophrenia: impairments, correlates, and treatment", Psychiatr Clin North Am, 29, pp.1033~1045 (2006)
17. Birchwood M, "Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation", Psychol Med, 19, pp.649~656 (1989)
18. Chemerinski E, "Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia", Compr Psychiatry, 43, pp.393~396 (2002)
19. Godbout R., "Sleep disturbance in schizophrenia, In Clinical Pharmacology of Sleep", pp.125~131 (2006), BirkhäEuser
20. West LJ, "The psychosis of sleep deprivation", Ann N Y Acad Sci, 96, pp.66~70 (1962)
21. Zarcone VP, "BPRS symptom factors and sleep variables in schizophrenia", Psychiatry Res, 66, pp.111~120 (1997)
22. DevillièFres P, "Delusion and sleep deprivation", Encephale, 22, pp.229~231 (1996)
23. Freeman D, "Insomnia and paranoia", Schizophr Res, 108, pp.280~284 (2009)
24. Luby ED, "Sleep deprivation: effects on behavior, thinking, motor performance, and biological energy transfer systems", Psychosom Med, 22, pp.182~192 (1960)
25. Czeisler CA, "Principles and Practices in Sleep Medicine", pp.2005, Elsevier
26. Hofstetter JR, "Sleep and daily activity preferences in schizophrenia: associations with neurocognition and symptoms", J Nerv Ment Dis, 191, pp.408~410 (2003)
27. Morgan R, "Circadian body temperature in chronic schizophrenia", Br J Psychiatry, 129, pp.350~354 (1976)
28. Van Cauter E, "Circadian and sleep-related endocrine rhythms in schizophrenia", Arch Gen Psychiatry, 48, pp.348~356 (1991)
29. Wirz-Justice A, "A schizophrenic patient with an arrhythmic circadian rest-activity cycle", Psychiatry Res, 73, pp.83~90 (1997)
30. Wirz-Justice A, "Disturbed circadian rest-activity cycles in schizophrenia patients: an effect of drugs?", Schizophr Bull, 27, pp.497~502 (2001)
31. Wulff K, "The suitability of actigraphy, diary data, and urinary melatonin profiles for quantitative assessment of sleep disturbances in schizophrenia: a case report", Chronobiol Int, 23, pp.485~495 (2006)
32. Fanget F, "Melatonin and schizophrenia", Encephale, 15, pp.505~510 (1989)
33. Ferrier IN, "Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight", Clin Endocrinol, 17, pp.181~187 (1982)
34. Rao ML, "Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptictreated schizophrenic patients and healthy subjects", Psychiatry Res, 34, pp.243~257 (1990)
35. Robinson S, "Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients", Acta Psychiatr Scand, 84, pp.221~224 (1991)
36. Thakore JH, "Increased visceral fat distribution in drug-naive and drugfree patients with schizophrenia", Int J Obes Relat Metab Disord, 26, pp.137~141 (2002)
37. Bernstein HG, "Hypothalamic nitric oxide synthase in affective disorder: focus on the suprachiasmatic nucleus", Cell Mol Biol, 51, pp.279~284 (2005)
38. Trbovic SM., "Schizophrenia as a possible dysfunction of the suprachiasmatic nucleus", Med Hypotheses, 74, pp.127~131 (2010)
39. Chen L, "Spontaneous sleep in mice with targeted disruptions of neuronal or inducible nitric oxide synthase genes", Brain Res, 973, pp.214~222 (2003)
40. Kalinchuk AV, "Inducible and neuronal nitric oxide synthases (NOS) have complementary roles in recovery sleep induction", Eur J Neurosci, 24, pp.1443~1456 (2006)
41. GöFder R, "Impairment of visuospatial memory is associated with decreased slow wave sleep in schizophrenia", J Psychiatr Res, 38, pp.591~599 (2004)
42. Hofstetter JR, "Quality of sleep in patients with schizophrenia is associated with quality of life and coping", BMC Psychiatry, 5, pp.13~ (2005)
43. Martin J, "Actigraphic estimates of circadian rhythms and sleep", wake in older schizophrenia patients, 2001, pp.47, 77~86
44. Ritsner M, "Perceived quality of life in schizophrenia: relationships to sleep quality", Qual Life Res, 13, pp.783~791 (2004)
45. Lu BS, "Circadian rhythm sleep disorders", Chest, 130, pp.1915~1923 (2006)
46. Sekimoto M, "Reduced frontal asymmetry of delta waves during all-night sleep in schizophrenia", Schizophr Bull, 33, pp.1307~1311 (2007)
47. Appleby L, "Sudden unexplained death in psychiatric in-patients", Br J Psychiatry, 176, pp.405~406 (2000)
48. Ruschena D, "Sudden death in psychiatric patients", Br J Psychiatry, 172, pp.331~336 (1998)
49. HeiläH, "Mortality among patients with schizophrenia and reduced psychiatric hospital care", Psychol Med, 35, pp.725~732 (2005)
50. Hennekens CH, "Schizophrenia and increased risks of cardiovascular disease", Am Heart J, 150, pp.1115~1121 (2005)
51. Hennekens CH, "Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia", J Clin Psychiatry, 68(Suppl 4), pp.4~7 (2007)
52. Saha S, "A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?", Arch Gen Psychiatry, 64, pp.1123~1131 (2007)
53. Newcomer JW., "Antipsychotic medications: metabolic and cardiovascular risk", J Clin Psychiatry, 68(Suppl 4), pp.8~13 (2007)
54. Bä}r KJ, "Loss of efferent vagal activity in acute schizophrenia", J Psychiatr Res, 39, pp.519~527 (2005)
55. Goff DC, "A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls", Schizophr Res, 80, pp.45~53 (2005)
56. Kato M, "Effects of sleep deprivation on neural circulatory control", Hypertension, 35, pp.1173~1175 (2000)
57. Weber NS, "Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey", Psychiatr Serv, 60, pp.1059~1067 (2009)
58. Birkenhäger WH, "Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension", Arch Intern Med, 161, pp.152~156 (2001)
59. Jindal R, "Cardiac risk and schizophrenia", J Psychiatry Neurosci, 30, pp.393~395 (2005)
60. Fedorowski A, "Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project)", Eur Heart J, 31, pp.85~91 (2010)
61. Tsuji H, "Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study", Circulation, 94, pp.2850~2855 (1996)
62. Bobes J, "Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort", Schizophr Res, 119, pp.101~109 (2010)
63. Birkenaes AB, "Sociodemographic characteristics and cardiovascular risk factors in patients with severe mental disorders compared with the general population", J Clin Psychiatry, 67, pp.425~433 (2006)
64. Dickerson FB, "Obesity among individuals with serious mental illness", Acta Psychiatr Scand, 113, pp.306~313 (2006)
65. Filik R, "The cardiovascular and respiratory health of people with schizophrenia", Acta Psychiatr Scand, 113, pp.298~305 (2006)
66. Susce MT, "Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey", J Clin Psychiatry, 66, pp.167~173 (2005)
67. Palik E, "Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics", Diabetes Res Clin Pract, 68(Suppl 1), pp.S60~S64 (2005)
68. Ryan MC, "The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia", Life Sci, 74, pp.1999~2008 (2004)
69. Björntorp P, "Metabolic implications of body fat distribution", Diabetes Care, 14, pp.1132~1143 (1991)
70. Kissebah AH, "Regional adiposity and morbidity", Physiol Rev, 74, pp.761~811 (1994)
71. Brunzell JD, "Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation", Diabetes Care, 31, pp.811~822 (2008), American College of Cardiology Foundation
72. Stanton JM., "Weight gain associated with neuroleptic medication: a review", Schizophr Bull, 21, pp.463~472 (1995)
73. Baptista T, "Body weight gain induced by antipsychotic drugs: mechanisms and management", Acta Psychiatr Scand, 100, pp.3~16 (1999)
74. Wirshing DA, "Novel antipsychotics: comparison of weight gain liabilities", J Clin Psychiatry, 60, pp.358~363 (1999)
75. Green AI, "Weight gain from novel antipsychotic drugs: need for action", Gen Hosp Psychiatry, 22, pp.224~235 (2000)
76. Stedman T, "The distribution of adipose tissue in female in-patients receiving psychotropic drugs", Br J Psychiatry, 162, pp.249~250 (1993)
77. Zimmermann U, "Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients", J Psychiatr Res, 37, pp.193~220 (2003)
78. Kim SF, "From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase", Proc Natl Acad Sci U S A, 104, pp.3456~3459 (2007)
79. Nasrallah H, "A review of the effect of atypical antipsychotics on weight", Psychoneuroendocrinology, 28(Suppl 1), pp.83~96 (2003)
80. Khazaal Y, "Eating and weight related cognitions in people with Schizophrenia : a case control study", Clin Pract Epidemiol Ment Health, 2, pp.29~ (2006)
81. Brömel T, "Serum leptin levels increase rapidly after initiation of clozapine therapy", Mol Psychiatry, 3, pp.76~80 (1998)
82. Leadbetter R, "Clozapine-induced weight gain: prevalence and clinical relevance", Am J Psychiatry, 149, pp.68~72 (1992)
83. Yum SY, "Schizophrenia and eating disorders", Psychiatr Clin North Am, 32, pp.809~819 (2009)
84. Brown S, "The unhealthy lifestyle of people with schizophrenia", Psychol Med, 29, pp.697~701 (1999)
85. McCreadie R, "Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study", BMJ, 317, pp.784~785 (1998)
86. McCreadie RG, "Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study", Br J Psychiatry, 183, pp.534~539 (2003)
87. McCreadie RG, "Dietary improvement in people with schizophrenia: randomised controlled trial", Br J Psychiatry, 187, pp.346~351 (2005)
88. Sentissi O, "Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review", Schizophr Bull, 34, pp.1189~1199 (2008)
89. Formiguera X, "Obesity: epidemiology and clinical aspects", Best Pract Res Clin Gastroenterol, 18, pp.1125~1146 (2004)
90. Murashita M, "Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia", Psychiatry Clin Neurosci, 61, pp.54~58 (2007)
91. Friedman JM, "The function of leptin in nutrition, weight, and physiology", Nutr Rev, 60, pp.S1~S14 (2002)
92. Eder U, "Association of olanzapine-induced weight gain with an increase in body fat", Am J Psychiatry, 158, pp.1719~1722 (2001)
93. Arranz B, "Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients", J Clin Psychiatry, 65, pp.1335~1342 (2004)
94. Atmaca M, "Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain", J Psychiatr Res, 41, pp.74~79 (2007)
95. Baptista T, "Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration", Pharmacopsychiatry, 34, pp.223~231 (2001)
96. Christie JE, "Corticosteroid secretion--clinical aspects. Plasma cortisol concentrations in the functional psychoses and Alzheimer type dementia: a neuroendocrine day approach in drug-free patients", J Steroid Biochem, 19, pp.247~250 (1983)
97. Gil-Ad I, "Diurnal rhythm of plasma beta endorphin, cortisol and growth hormone in schizophrenics as compared to control subjects", Psychopharmacology, 88, pp.496~499 (1986)
98. Ryan MC, "Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia", Am J Psychiatry, 160, pp.284~289 (2003)
99. Walder DJ, "Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia", Biol Psychiatry, 48, pp.1121~1132 (2000)
100. Whalley LJ, "Selective increase in plasma luteinising hormone concentrations in drug free young men with mania", Br Med J, 290, pp.99~102 (1985)
101. Lammers CH, "Combined dexamethasone", corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II, 1995, pp.38, 803~807
102. Mück-Seler D, "Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients", Biol Psychiatry, 45, pp.1433~1439 (1999)
103. Pivac N, "Platelet 5-HT levels and hypothalamic-pituitary-adrenal axis activity in schizophrenic patients with positive and negative symptoms", Neuropsychobiology, 36, pp.19~21 (1997)
104. Ottosson M, "The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue", J Clin Endocrinol Metab, 79, pp.820~825 (1994)
105. Townsend MH, "Blood pressure, heart rate, and anxiety in schizophrenia", Psychiatry Res, 151, pp.155~157 (2007)
106. Afzal N, "Stress axis dysfunction: A common finding in schizophrenia and the metabolic syndrome?, In Metabolic Effects of Psychotropic Drugs. Mod Trends Pharmacopsychiatry", pp.82~89 (2009), Karger
107. Bradley AJ, "A systematic review of hypothalamic- pituitary-adrenal axis function in schizophrenia: implications for mortality", J Psychopharmacol, 24(4 Suppl), pp.91~118 (2010)
108. Pasquali R, "The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome", Ann N Y Acad Sci, 1083, pp.111~128 (2006)
109. Patel SB, "Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease", Curr Hypertens Rep, 10, pp.131~137 (2008)
110. Ukkola O, "Low plasma ghrelin concentration is an indicator of the metabolic syndrome", Ann Med, 38, pp.274~279 (2006)
111. Bushe C, "Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia", Br J Psychiatry Suppl, 47, pp.S67~S71 (2004)
112. Cohen D, "Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders", Diabetes Care, 29, pp.786~791 (2006)
113. McEvoy JP, "Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III", Schizophr Res, 80, pp.19~32 (2005)
114. Holt RI, "Diabetes and schizophrenia2005: are we any closer to understanding the link?", J Psychopharmacol, 19(6 Suppl), pp.56~65 (2005)
115. Yasui-Furukori N, "Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine", Clin Psychiatry, 70, pp.95~100 (2009)
116. Cohn TA, "Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report", Can J Psychiatry, 51, pp.382~386 (2006)
117. van Nimwegen LJ, "Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism", J Clin Endocrinol Metab, 93, pp.572~577 (2008)
118. Schmidt MI, "Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators", Metabolism, 45, pp.699~706 (1996)
119. Meyer G, "Glucocorticoid-induced insulin resistance and diabetes mellitus. Receptor-, postreceptor mechanisms, local cortisol action, and new aspects of antidiabetic therapy", Med Klin, 98, pp.266~270 (2003)
120. Dinan TG., "Stress and the genesis of diabetes mellitus in schizophrenia", Br J Psychiatry Suppl, 47, pp.S72~S75 (2004)
121. Ogawa Y, "Total sleep deprivation elevates blood pressure through arterial baroreflex resetting: a study with microneurographic technique", Sleep, 26, pp.986~989 (2003)
122. Tochikubo O, "Effects of insufficient sleep on blood pressure monitored by a new multibiomedical recorder", Hypertension, 27, pp.1318~1324 (1999)
123. Robillard R, "Sleep deprivation increases blood pressure in healthy normotensive elderly and attenuates the blood pressure response to orthostatic challenge", Sleep, 34, pp.335~339 (2011)
124. Leproult R, "Sleep loss results in an elevation of cortisol levels the next evening", Sleep, 20, pp.865~870 (1997)
125. Spiegel K, "Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite", Ann Intern Med, 141, pp.846~850 (2004)
126. Cappuccio FP, "Meta-analysis of short sleep duration and obesity in children and adults", Sleep, 31, pp.619~626 (2008)
127. Yildiz BO, "Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity", Proc Natl Acad Sci U S A, 101, pp.10434~10439 (2004)
128. Dugovic C, "High corticosterone levels in prenatally stressed rats predict persistent paradoxical sleep alterations", J Neurosci, 19, pp.8656~8664 (1999)
129. Van Cauter E, "Circadian modulation of glucose and insulin responses to meals: relationship to cortisol rhythm", Am J Physiol, 262, pp.E467~E475 (1992)
130. Aparicio NJ, "Circadian variation of the blood glucose, plasma insulin and human growth hormone levels in response to an oral glucose load in normal subjects", Diabetes, 23, pp.132~137 (1974)
131. Carroll KF, "Diurnal variation in glucose tolerance and in insulin secretion in man", Diabetes, 22, pp.333~348 (1973)
132. Zimmet PZ, "Diurnal variation in glucose tolerance: associated changes in plasma insulin, growth hormone, and non-esterified fatty acids", Br Med J, 1, pp.485~488 (1974)
133. Millar-Craig MW, "Circadian variation of blood-pressure", Lancet, 1, pp.795~797 (1978)
134. Di Iorio A, "Blood pressure rhythm and prevalence of vascular events in hypertensive subjects", Age Ageing, 28 (1999)
135. Hoshide S, "Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives", Am J Hypertens, 16, pp.434~438 (2003)
136. Van Cauter E, "Roles of circadian rhythmicity and sleep in human glucose regulation", Endocr Rev, 18, pp.716~738 (1997)
137. Scheer FA, "Adverse metabolic and cardiovascular consequences of circadian misalignment", Proc Natl Acad Sci U S A, 106, pp.4453~4458 (2009)
138. Maury E, "Circadian rhythms and metabolic syndrome: from experimental genetics to human disease", Circ Res, 106, pp.447~462 (2010)
139. Gejman PV, "The role of genetics in the etiology of schizophrenia", Psychiatr Clin North Am, 33, pp.35~66 (2010)
140. Clarke MC, "Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia", Am J Psychiatry, 166, pp.1025~1030 (2009)
141. Mä�ki P, "Schizophrenia in the offspring of antenatally depressed mothers in the northern Finland 1966 birth cohort: relationship to family history of psychosis", Am J Psychiatry, 167, pp.70~77 (2010)
142. van Os J, "Confirmation of synergy between urbanicity and familial liability in the causation of psychosis", Am J Psychiatry, 161, pp.2312~2314 (2004)
143. van Os J, "The environment and schizophrenia", Nature, 468, pp.203~212 (2010)
144. Lamont EW, "The role of circadian clock genes in mental disorders", Dialogues Clin Neurosci, 9, pp.333~342 (2007)
145. Mansour HA, "Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia", Bipolar Disord, 11, pp.701~710 (2009)
146. Mansour HA, "Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia", Genes Brain Behav, 5, pp.150~157 (2006)
147. Mongrain V, "Clock genes in health and diseases", J Appl Biomed, 7, pp.15~33 (2009)
148. Durgan DJ, "The circadian clock within the cardiomyocyte is essential for responsiveness of the heart to fatty acids", J Biol Chem, 281, pp.24254~24269 (2006)
149. Kennaway DJ, "Metabolic homeostasis in mice with disrupted Clock gene expression in peripheral tissues", Am J Physiol Regul Integr Comp Physiol, 293, pp.R1528~R1537 (2007)
150. Ohkura N, "CLOCK regulates circadian platelet activity", Thromb Res, 123, pp.523~527 (2009)
151. Viola F, "Time-domain optimized near-field estimator for ultrasound imaging: initial development and results", IEEE Trans Med Imaging, 27, pp.99~110 (2008)
152. Viswambharan H, "Mutation of the circadian clock gene Per2 alters vascular endothelial function", Circulation, 115, pp.2188~2195 (2007)
153. Turek FW, "Obesity and metabolic syndrome in circadian Clock mutant mice", Science, 308, pp.1043~1045 (2005)
154. Boivin DB, "Doseresponse relationships for resetting of human circadian clock by light", Nature, 379, pp.540~542 (1996)
155. Edinger JD, "Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial", JAMA, 285, pp.1856~1864 (2001)
156. Espie CA, "The clinical effectiveness of cognitive behaviour therapy for chronic insomnia: implementation and evaluation of a sleep clinic in general medical practice", Behav Res Ther, 39, pp.45~60 (2001)
157. Khalsa SB, "A phase response curve to single bright light pulses in human subjects", J Physiol, 549, pp.945~952 (2003)
158. Morin CM, "Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy", Am J Psychiatry, 151, pp.1172~1180 (1994)
159. Wright KP Jr, "Intrinsic period and light intensity determine the phase relationship between melatonin and sleep in humans", J Biol Rhythms, 20, pp.168~177 (2005)

관련 논문AI추천